Bladder Cancer Coverage from Every Angle
Editor:
Thomas Flaig, MD
Advertisement
Advertisement

Available Clinical Trials

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG) Therapy
A Phase II Study of Avelumab in Combination with Bladder-Directed Radiation in Cisplatin-Ineligible Patients with Muscle-Invasive Urothelial Carcinoma of the Bladder
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients with Advanced Urothelial Carcinoma
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
A Phase III Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer
A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy.
Evaluating Cystectomy with Perioperative Pembrolizumab and Perioperative Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
Phase 3 Study to Evaluate Perioperative Pembrolizumab & Neoadjuvant Chemotherapy versus Perioperative Placebo & Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Tissue and Body Fluid Analysis from Patients with Bladder Cancer and Other Urothelial Cancers of the Urinary Tract
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.